Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1443962
This article is part of the Research Topic The Exciting Opportunities and Challenges for Targeting “HER2 low” Breast Cancers and Beyond View all 7 articles

Monitoring and Management of Adverse Effects Associated with Trastuzumab Deruxtecan: A UAE-specific Consensus

Provisionally accepted
Emad Anwar Dawoud Emad Anwar Dawoud 1*Fathi Azribi Fathi Azribi 2Aref Chehal Aref Chehal 3Shaheenah Dawood Shaheenah Dawood 4Sayyed Hammad Sayyed Hammad 5Dina Hamza Dina Hamza 5Hassan Jaafar Hassan Jaafar 6Hussam Marashi Hussam Marashi 1
  • 1 Tawam Hospital, Al Ain, United Arab Emirates
  • 2 American Hospital Dubai, Dubai, United Arab Emirates
  • 3 Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates
  • 4 Mediclinic City Hospital, Dubai, United Arab Emirates
  • 5 Dubai Hospital, Dubai, United Arab Emirates
  • 6 Burjeel Hospital, Abu Dhabi, Abu Dhabi, United Arab Emirates

The final, formatted version of the article will be published soon.

    Breast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancerrelated mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for patients in metastatic settings. The recognition of "HER2-low" expression as a targetable category has caused a paradigm shift in the management of breast cancer. Although initially developed to target HER2-positive breast cancer, trastuzumab deruxtecan (T-DXd), an ADC, has now also been approved to treat metastatic or unresectable HER2-low breast cancers. Despite the inherent specificity of an ADC, the risk of off-site toxicity exists and is an essential component while assessing the risk-benefit ratio of the treatment. Developing strategies to balance efficacy and safety is crucial, especially for newly approved therapies like T-DXd. Regional perspectives, cultural beliefs, and demographic factors influence treatment decisions and outcomes. The objective of this paper is to establish a UAE-specific consensus among oncologists on practical T-DXd treatment considerations and management of associated side effects. Establishing a consensus on monitoring and managing T-DXd side effects among experts can promote informed decision-making.

    Keywords: HER2, metastatic breast cancer, trastuzumab deruxtecan, T-DXd, targeted therapy, Antibody-drug conjugates, adverse effects

    Received: 05 Jun 2024; Accepted: 16 Dec 2024.

    Copyright: © 2024 Dawoud, Azribi, Chehal, Dawood, Hammad, Hamza, Jaafar and Marashi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Emad Anwar Dawoud, Tawam Hospital, Al Ain, United Arab Emirates

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.